This anti-ORF45 has been shown to purify different populations of ORF45 as well as enable the targeted depletion or enrichment of subpopulations of ORF45. This anti-ORF45 was generated using a baculovirus-synthesized ORF45 as an antigen.
| Inventor | Institute |
|---|---|
| Fanxiu Zhu | Florida State University Research Foundation |
| Cat. #: | 160637 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Genetics;Microbiology |
| Application: | IP ; WB |
| Target: | Open Reading Frame 45 |
| Reactivity: | Other Species |
| Host: | Mouse |
| Class: | Monoclonal |
| Product description: | Kaposi's sarcoma-associated herpesvirus (KSHV) has been identified as the causative agent of Kaposi's sarcoma, the most common malignancy in HIV-infected individuals. KSHV has also been shown to be be associated with two lymphoproliferative diseases (Fu et al., 2015). ORF45 (tegument) is a gene associated with the lytic viral life cycle of KSHV and has been shown to have multiple functions throughout the viral life cycle. ORF45 is a crucial component of progeny virion production in conjunction with ORF33. ORF45 binds to and stabilizes ORF33. This anti-ORF45 has been shown to purify different populations of ORF45 as well as enable the targeted depletion or enrichment of subpopulations of ORF45. This anti-ORF45 was generated using a baculovirus-synthesized ORF45 as an antigen. |
|---|---|
| Conjugation: | Unconjugated |
| Isotype: | IgG |
| Immunogen: | A baculovirus-synthesized ORF45 protein was used as an antigen |
| Target background: | Kaposi's sarcoma-associated herpesvirus (KSHV) has been identified as the causative agent of Kaposi's sarcoma, the most common malignancy in HIV-infected individuals. KSHV has also been shown to be be associated with two lymphoproliferative diseases (Fu et al., 2015). ORF45 (tegument) is a gene associated with the lytic viral life cycle of KSHV and has been shown to have multiple functions throughout the viral life cycle. ORF45 is a crucial component of progeny virion production in conjunction with ORF33. ORF45 binds to and stabilizes ORF33. This anti-ORF45 has been shown to purify different populations of ORF45 as well as enable the targeted depletion or enrichment of subpopulations of ORF45. This anti-ORF45 was generated using a baculovirus-synthesized ORF45 as an antigen. |
|---|
| Format: | Liquid |
|---|---|
| Shipping conditions: | Dry ice |
| References: |
Wu et al. 2016. J Virol. 90(4):1741-56. PMID: 26637455. Gillen et al. 2015. J Virol. 89(9):4918-31. PMID: 25694600. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151023 | Anti-IL12 [1-1D5] |
Key Info
Anti-IL12 [1-1D5]
|
View Tool | |||||||||||||||||||
| 151027 | Anti-HSVICP8 [10A3] |
Key Info
Anti-HSVICP8 [10A3]
|
View Tool | |||||||||||||||||||
| 151033 | Anti-HSVUL42 [13C9] |
Key Info
Anti-HSVUL42 [13C9]
|
View Tool | |||||||||||||||||||
| 151040 | Anti-CD11 & CD18 [24] |
Key Info
Anti-CD11 & CD18 [24]
|
View Tool | |||||||||||||||||||
| 151020 | Anti-CyclinB1 [V143.1] |
Key Info
Anti-CyclinB1 [V143.1]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.